Quantum Surgical’s Post

If you’ll be at #ISET2024 this week, check out the poster on the #ULTRAembolic: “Novel polyelectrolyte hydrogel embolic evaluation in pre-clinical tumor and hemorrhage models”    #oncology #embolization #interventionalradiology #interventionaloncology

📚 We are excited to share a new publication about the E2-RADIatE #OligoCare cohort, the largest prospective registry cohort on oligometastatic disease. This interim analysis of approximately 1600 oligometastatic patients aimed to evaluate acute toxicity within 6 months following stereotactic body radiotherapy (SBRT). Toxicity within 6 months was low, confirming that SBRT is safe to use in the oligometastatic setting. View the publication: https://lnkd.in/easnTr8Z #CancerResearch #ClinicalTrials #Oncology #E2RADIatE #SBRT

The Response Assessment in Neuro-Oncology (RANO) group provides various central nervous system-related tumor response criteria and guidance for assessments. In our on-demand webinar MERIT experts discuss the principles and recommendations of RANO response criteria for high grade glioma (HGG) and the imaging endpoint information that needs to be collected for #clinicaltrials. Watch now: https://lnkd.in/g79kJpq9 #oncology #medicalimaging #clinicalresearch #MERITCROwebinar #webinar #MERITCRO #YourClinicalEndpointExpert #oncologyresearch #oncologytrials

Thank you to Michael Gensheimer, M.D., Clinical Associate Professor of Radiation Oncology at Stanford University School of Medicine, for joining us yesterday as part of our AI in Medicine Seminar Series. His talk was entitled "Machine Learning for Clinical Decision Support in Oncology." #artificialintelligence #aiinmedicine #machinelearning #oncology #radiationoncology #radiationtherapy

Learn from #RECIST expert, Dr. Oliver Bohnsack how response evaluation in #Oncology research can be improved – and in many cases, fewer #ClinicalTrial patients lost – by using #irRECIST to assess tumor burden. https://lnkd.in/dKiC-RTe #MedicalImaging #ClinicalTrials #ChooseCalyx

Learn from #RECIST expert, Dr. Oliver Bohnsack how response evaluation in #Oncology research can be improved – and in many cases, fewer #ClinicalTrial patients lost – by using #irRECIST to assess tumor burden. https://lnkd.in/gfg2avj3 #MedicalImaging #ClinicalTrials #ChooseCalyx

Learn from #RECIST expert, Dr. Oliver Bohnsack how response evaluation in #Oncology research can be improved – and in many cases, fewer #ClinicalTrial patients lost – by using #irRECIST to assess tumor burden. https://lnkd.in/deptk9qN #MedicalImaging #ClinicalTrials #ChooseCalyx

Learn from RECIST expert, Dr. Oliver Bohnsack how response evaluation in #Oncology research can be improved – and in many cases, fewer #ClinicalTrial patients lost – by using irRECIST to assess tumor burden. https://lnkd.in/gbXSW6RW #MedicalImaging #ClinicalTrials #ChooseCalyx #ASCO23 

Learn from #RECIST expert, Dr. Oliver Bohnsack how response evaluation in #Oncology research can be improved – and in many cases, fewer #ClinicalTrial patients lost – by using #irRECIST to assess tumor burden. https://lnkd.in/e7yNN7ND #MedicalImaging #ClinicalTrials #ChooseCalyx

Learn from #RECIST expert, Dr. Oliver Bohnsack how response evaluation in #Oncology research can be improved – and in many cases, fewer #ClinicalTrial patients lost – by using #irRECIST to assess tumor burden. https://lnkd.in/es_HeJKt #MedicalImaging #ClinicalTrials #ChooseCalyx